Skip to content

Iovance Biotherapeutics, Inc. IOVA Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Immunome logo
ImmunomeIMNM
-$79K
Enliven Therapeutics logo
Enliven TherapeuticsELVN
-$26.5K-864%

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.98B+32.4%
Enterprise value$1.83B+33.2%
P/S6.9×-0.1×

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s gain/loss on asset sales?
Iovance Biotherapeutics, Inc. (IOVA) reported gain/loss on asset sales of -$28K in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s gain/loss on asset sales changed year-over-year?
Iovance Biotherapeutics, Inc.'s gain/loss on asset sales increased by 36.4% year-over-year, from -$44K to -$28K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.